<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        37-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VOSTRAN 2MG/ML SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MS Pharma " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MS Pharma 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Vostran </strong>contains the active substance ondansetron, which belongs to a group of medicines</p><p>called anti-emetics.</p><p>Vostran Injection is used for</p><p> Preventing nausea (feel sick) and vomiting (be sick) caused by</p><p>o chemotherapy for cancer in adults and in children aged &ge;6 months.</p><p>o radiotherapy for cancer in adults</p><p> Preventing and treatment of nausea and vomiting after surgery in adults and in children aged &ge; 1 month.</p><p>Ask your doctor, nurse or pharmacist if you would like any further explanation about this uses.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Vostran </strong><strong>Injection:</strong></p><p>- If you or your child are allergic to Ondansetron or any of the other ingredients of this medicine (listed in section 6)or to any similar medicines e.g. granisetron or dolasetron.</p><p>- If you or your child are taking Apomorphine (a medicine used to treat Parkinson&rsquo;s disease)</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using <strong>Vostran </strong>Injection</p><p>- if you or your child have a blockage in your gut or suffer from severe constipation Ondansetron can make these conditions worse.</p><p>- if you or your child have liver problems</p><p>- if you or your child have ever had problem with your heart or are taking medicines used to treat heart problems (e.g. congestive heart failure which causes shortness of breath and swollen ankles)</p><p>- if you or your child have an uneven heart beat (arrhythmias)</p><p>- if you or your child are allergic to medicines similar to ondansetron, such as granisetron or palonosetron</p><p>- if you or your child are having surgery to remove your tonsils, because treatment with Vostran may hide symptoms of internal bleeding</p><p>- if you or your child have problems with the levels of salts in your blood, such as potassium, sodium and magnesium</p><p>If you are not sure if any of the above apply to you or your child, talk to your doctor, nurse or pharmacist before having Vostran injection.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Vostran </strong><strong>injection</strong></p><p>Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines, natural supplements or vitamins or minerals.</p><p> In particular, tell your doctor, nurse or pharmacist if you or your child are taking any of the following medicines:</p><p>Phenytoin (used to treat epilepsy &amp; heart arrhythmias) The effect of ondansetron may be weakened.</p><p> Carbamazepine (used to treat epilepsy &amp; neuralgic pain) The effect of ondansetron may be weakened.</p><p> Rifampicin used to treat infections such as tuberculosis (TB) The effect of ondansetron may be</p><p>weakened.</p><p> Antibiotics such as erythromycin or ketoconazole</p><p> Anti-arrhythmic medicines (used to treat an uneven heart beat) such as amiodarone</p><p> Beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines such as atenolol or timolol</p><p> Tramadol (used to treat pain) The painkilling effect of Tramadol may be weakened.</p><p> Apomorphine (medicine used to treat Parkinson&rsquo;s disease) strong drop in blood pressure and loss of consciousness with simultaneous application of (ondansetron) have been reported with apomorphine.</p><p> Medicines that affect the heart (such as haloperidol or methadone)</p><p> Cancer medicines (especially anthracyclines such as doxorubicin, daunorubicin or trastuzumab)</p><p> SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including</p><p>fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</p><p> SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine</p><p>Contact your doctor. It may be necessary to adjust the dose.</p><p>&nbsp;</p><p><strong>Vostran </strong><strong>injection with food and drink</strong></p><p>You may use Vostran injection independently of food and drink</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility:</strong></p><p><strong>Pregnancy:</strong></p><p>Because of insufficient experience the use of Vostran injection in pregnancy is not recommended. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using Vostran injection.</p><p>&nbsp;</p><p><strong>Breast &ndash;Feeding:</strong></p><p>The ondansetron in Vostran Injection may pass into mothers&#39; milk. Therefore mothers receiving</p><p><strong>Vostran </strong>injection should not breast-feed their baby</p><p>If you are breast-feeding, ask your doctor or pharmacist for advice before using Vostran injection.</p><p>&nbsp;</p><p><strong>Driving and using machines:</strong></p><p>Vostran injection will not affect your ability to drive or operate machinery.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients in this medicine</strong></p><p>This medicinal product contains 2.5 mmol (or 57.9 mg) sodium per maximum daily dose of 32 mg. To be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Vostran Injection is normally given by a nurse or doctor. The dose you have been prescribed will</p><p>depend on the treatment you are having.</p><p><strong>To prevent nausea and vomiting from chemotherapy or radiotherapy</strong></p><p><strong>Adults</strong></p><p>On the day of chemotherapy or radiotherapy the recommended adult dose is 8 mg given by an injection into your vein or muscle, just before your treatment, and another 8 mg twelve hours later.</p><p>The usual adult intravenous dose does not exceed 8 mg.</p><p>On the following days</p><p>&bull; After chemotherapy, your medicine will usually be given by mouth as an 8 mg Vostran tablet or 10ml (8 mg) Vostran syrup.&bull; oral dosing can commence twelve hours after the last intravenous dose and may be continued for up to 5 days.</p><p>If your chemotherapy or radiotherapy is likely to cause severe nausea and vomiting, you or your child may be given more than the usual dose of Vostran Injection. Your doctor will decide this.</p><p><strong>To prevent nausea and vomiting from chemotherapy</strong></p><p>Children aged over 6 months and adolescents</p><p>The doctor will decide the dose based on the child&rsquo;s weight or size (body surface area).</p><p>On the day of chemotherapy</p><p>&bull; the first dose is given by an injection into the vein, just before your child&rsquo;s treatment. After</p><p>chemotherapy, your child&rsquo;s medicine will usually be given by mouth as tablets or syrup.</p><p>On the following days oral dosing can commence twelve hours after the last intravenous dose and may be continued for up to 5 days.</p><p><strong>To prevent and treat nausea and vomiting after an operation</strong></p><p><strong>Adults:</strong></p><p>&bull; The usual dose for adults is 4 mg given by an injection into your vein or an injection into your muscle.</p><p>&nbsp;</p><p><strong>For prevention this will be given just before your operation.</strong></p><p><strong>Children:</strong></p><p>&bull; For children aged over 1 month and adolescents, the doctor will decide the dose. The maximum dose is 4 mg given as a slow injection into the vein. For prevention this will be given just before the operation.</p><p><strong>Patients with moderate or severe liver problems</strong></p><p>The total daily dose should not be more than 8 mg.</p><p><strong>If you or your child keep feeling or being sick</strong></p><p>Vostran injection should start to work soon after having the injection. If you or your child continue to be sick or feel sick, tell your doctor or nurse.</p><p><strong>If you or your child have more Vostran Injection than you should</strong></p><p>Your doctor or nurse will give you or your child Vostran injection so it is unlikely that you or your child will receive too much. If you think you or your child have been given too much or have missed a dose, tell your doctor or nurse.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>SERIOUS SIDE-EFFECTS</strong></p><p><strong>Allergic Reactions</strong></p><p>If you or your child have an allergic reaction, tell your doctor or a member of the medical staff straight away. The signs may include:</p><p>&bull; sudden wheezing and chest pain or chest tightness</p><p>&bull; swelling of your eyelids, face, lips, mouth or tongue</p><p>&bull; skin rash &ndash; red spots or lumps under your skin (hives) anywhere on your body</p><p>&bull; collapse</p><p><strong>Less serious side-effects:</strong></p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p> Headache</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p> Sensations of flushing or warmth</p><p> Constipation</p><p> Changes to liver function test results (if you have Vostran</p><p>injection with a medicine called cisplatin, otherwise this side effect is uncommon)</p><p> Irritation and redness at the site of injection</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p> Seizures (fits or convulsions)</p><p> Unusual body movements or shaking</p><p> Uneven heart beat</p><p> Chest pain</p><p> Low blood pressure, which can make you feel faint or dizzy</p><p> Hiccups</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p> Feeling dizzy or light headed</p><p> Blurred vision</p><p> Disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)</p><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><p> Poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the Vial or carton after EXP. The expiry date refers to last day of that month.</p><p>Do not store above 30&deg;. protect from light.</p><p>Do not use this medicine if you notice container is damaged or particles / crystals are visible.</p><p>Do not throw away any medicine via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient in Vostran Injection is ondansetron (as hydrochloride dihydrate).</p><p>Each ml of solution for injection or infusion contains 2 mg ondansetron (as ondansetron hydrochloride dihydrate)</p><p>Each Vial of 2ml contains 4mg of ondansetron (as ondansetron hydrochloride dihydrate).</p><p>Each Vial of 4ml contains 8mg of ondansetron (as ondansetron hydrochloride dihydrate).</p><p>The other ingredients are citric acid monohydrate, sodium citrate, sodium chloride, sodium hydroxide&nbsp;&nbsp; and water for Injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vostran Injection is a clear colourless solution for injection or infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>MS Pharma- Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aug-19
SPM190282

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فوستران على المادة الفعالة أوندانسيترون، والتي تنتمي إلى مجموعة من الأدوية تُسمّى مضادات القيء.</p><p dir="RTL"><strong>تستخدم حقن فوستران في الآتي: </strong></p><p dir="RTL">الوقاية من الشعور بالغثيان (الشعور بالتعب) والقيء والناتج عن:</p><p dir="RTL">العلاج الكيماوي للسرطان، في حالات البالغين والأطفال الذين يبلغون من العمر 6 أعوام فأكثر.</p><p dir="RTL">العلاج الإشعاعي للسرطان في البالغين.</p><p dir="RTL">الوقاية والعلاج من الغثيان والقيء بعد العمليات الجراحية في حالات البالغين والأطفال البالغين من العمر شهر واحد فأكثر.</p><p dir="RTL">استشر الطبيب أو الممرضة أو الصيدلي إذا كانت لديك أية استفسارات حول استخدام هذا الدواء.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستخدم فوستران في الحالات الآتية:</strong></p><p dir="RTL">- إذا كنت تعاني أنت أو طفلك من حساسية مفرطة لمادة أوندانسيترون أو لأي مكونات أخرى في هذا الدواء (من المكونات المذكورة في الفقرة 6) أو لأية أدوية مشابهة مثل دواء جرانيسترون أو دولاسيترون.</p><p dir="RTL">إذا كنت أنت أو طفلك تتناول دواء أبومورفين (دواء يستخدم في علاج مرض باركينسون)</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">استشر الطبيب أو الصيدلي أو الممرضة قبل تناول هذا الدواء.</p><p dir="RTL">إذا كنت تعاني من انسداد في الأمعاء أو من امساك شديد، فإن تناول فوستران قد يسيء من هذه الحالة.</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكبد.</p><p dir="RTL">إذا سبق وعانيت من مشاكل في القلب أو إذا كنت تتناول أدوية تستخدم في علاج أمراض القلب (مثل فشل القلب المحتقن والذي يتسبب في حدوث قصر في النفس وتورم في الكاحل).</p><p dir="RTL">إذا كنت تعاني من عدم انتظام في ضربات القلب (عدم انتظام إيقاع ضربات القلب).</p><p dir="RTL">إذا كنت تعاني من حساسية لأدوية مشابهة لدواء فوستران مثل دواء جرانيسترون أو بالونوسيترون.</p><p dir="RTL">إذا كنت أنت أو طفلك قد خضعت لعملية لاستئصال اللوزتين، وذلك لأن تناول هذا الدواء قد يتسبب في إخفاء أعراض النزيف الداخلي.</p><p dir="RTL">إذا كنت تعاني من مشكلة في مستويات الملح في الدم، مثل البوتاسيوم والصوديوم والماغنسيوم.</p><p dir="RTL">يجب استشارة الطبيب أو الممرضة أو الصيدليّ قبل تناول هذا الدواء في حالة عدم تأكدك إن كانت أي من تلك الأمور السابقة تنطبق عليك أو على طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع دواء فوستران </strong></p><p dir="RTL">يجب عليك إخبار الطبيب أو الصيدليّ إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو يحتمل تناولك للأدوية بما في ذلك المكملات العشبية أو الفيتامينات أو المعادن.</p><p dir="RTL">وعلى وجه الخصوص؛ فيجب إخبار الطبيب أو الممرضة أو الصيدلي إذا كنت تتناول أي من هذه الأدوية التالية: فينيتوين (يستخدم في علاج الصرع وعدم انتظام ضربات القلب). حيث أنه قد يتسبب في إضعاف تأثير دواء فوستران.</p><p dir="RTL">كاربامازيبن (يستخدم في علاج الصرع والألم العصبي)، حيث أنه قد يتسبب في إضعاف تأثير دواء فوستران.</p><p dir="RTL">ريفامبسين (يستخدم في علاج العدوى مثل مرض الدرن / السلّ)، حيث أنه قد يتسبب في إضعاف تأثير دواء فوستران.</p><p dir="RTL">مضادات حيوية مثل دواء إريثرومايسن أو كيتوكونازول.</p><p dir="RTL">- الأدوية المضادة لاختلال ضربات القلب (تستخدم في علاج عدم انتظام ضربات القلب)، مثل أميودارون</p><p dir="RTL">حاصرات مستقبلات بيتا التي تستخدم في علاج بعض مشكلات القلب أو العين أو اضطراب القلق أو في الوقاية من الصداع النصفي مثل دواء أتينولول أو تيمولول.</p><p dir="RTL">ترامادول (يستخدم في تسكين الألم)، قد يتسبب الدواء في إضعاف تأثير دواء ترامادول المُسكن للألم.</p><p dir="RTL">أبومورفين (دواء يستخدم في علاج مرض باركينسون)، تم الإبلاغ عن حدوث انخفاض قوي في ضغط الدم وفقدان للوعي عند تناول دواء فوستران مع دواء أبومورفين في نفس الوقت.</p><p dir="RTL">الأدوية التي تؤثر على القلب (مثل دواء هالوبريدول وميثادون)</p><p dir="RTL">أدوية علاج السرطان (خاصة أدوية أنثراسيكلين مثل دوكسوروبيسين أو دانوروبيسين أو تراستوزوماب).</p><p dir="RTL">مثبطات السيروتونين الانتقائية (SSRIs) تستخدم في علاج الاكتئاب و / أو اضطراب القلق وتشمل الأدوية التالية: فلوكزيتين، باروكستين، سيرترالين، نبتة سانت جونز ، فلوفوكسامين، سيتالوبرام، إيسيتالوبرام.</p><p dir="RTL">مثبطات السيروتونين والنورأدرينالين (SNRIs) التي تستخدم في علاج الاكتئاب و / أو اضطراب القلق وتشمل الأدوية التالية: فينلافاكزين أو دولوكسيتين.</p><p dir="RTL">استشر الطبيب لأنه قد يكون من المهم إجراء تعديل على جرعتك من الدواء. .</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول حقن فوستران مع الأطعمة والمشروبات</strong></p><p dir="RTL">يمكن تناول دواء فوستران بغض النظر عن تناول أية أطعمة أو مشروبات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير الدواء على الحمل والرضاعة الطبيعية والخصوبة:</strong></p><p dir="RTL"><strong>الحمل:</strong></p><p dir="RTL">لا ينصح بتناول دواء فوستران أثناء الحمل لعدم وجود تجارب كافية حول استخدامه أثناء الحمل.&nbsp; يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية:</strong></p><p dir="RTL">قد تُفرز المادة الفعالة في دواء فوستران في لبن الأم.&nbsp; وبناء على ذلك؛ فيجب أن تمتنع الأمهات اللاتي تتناول هذا الدواء عن الرضاعة الطبيعية لأطفالهن.</p><p dir="RTL">ينصح باستشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات اللاتي تقمن بالرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">لا يؤثر فوستران على القدرة على القيادة أو استخدام الآلات.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات هذا الدواء:</strong></p><p dir="RTL">يحتوي هذا الدواء على 2.5 مل مول (أو 57.9 ملغم) من الصوديوم في أقصى جرعة يومية 32 ملغم. لذلك يجب أخذ ذلك الأمر بعين الاعتبار في المرضى الملتزمين بحمية غذائية قليلة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول هذا الدواء وفقًا لتعليمات الطبيب. يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك.</p><p dir="RTL">عادة ما يُعطى إليك هذا الدواء بواسطة الطبيب أو الممرضة. ستعتمد الجرعة الموصوفة لك على العلاج الذي تتناوله.</p><p dir="RTL">يستخدم في الوقاية من الشعور بالغثيان والقيء الناتج من العلاج الكيماوي أو العلاج الإشعاعي</p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">الجرعة الموصى بها للمرضى البالغين في يوم تلقي العلاج الكيماوي أو العلاج الإشعاعي هي 8 ملغم، تعطى عبر الحقن في الوريد أو العضل مباشرة قبل بدء العلاج. على أن تُعطى جرعة أخري مقدارها 8 ملغم بعد مرور 12 ساعة.&nbsp;</p><p dir="RTL">عادة لا تتجاوز الجرعة المأخوذة عبر الوريد في المرضى البالغين 8 ملغم.</p><p>&nbsp;</p><p dir="RTL">&nbsp;في الأيام التالية:</p><p dir="RTL">بعد العلاج الكيماوي؛ في الأغلب سيتم تناول الدواء عبر الفم، قرص 8 ملغم أو شراب 10 مل (8 ملغم). يمكن البدء في تناول الدواء عبر الفم بعد 12 ساعة من أخذ آخر جرعة وريدية، على أن يستمر في تناوله لمدة تصل إلى 5 أيام.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كان من المرجح أن يتسبب العلاج الكيماوي أو الإشعاعي في الغثيان والقيء الشديد، فقد يتم إعطاؤك جرعة أكبر من المعتاد من دواء فوستران.&nbsp;&nbsp; سيتولى الطبيب تقرير ذلك الأمر.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>يستخدم في الوقاية من الشعور بالغثيان والقيء الناتج من العلاج الكيماوي</strong></p><p dir="RTL">الأطفال البالغون من العمر ما يزيد عن 6 أشهر والمراهقون</p><p dir="RTL">سيتولى الطبيب تحديد الجرعة المناسبة للطفل بناء على ووزن الطفل (مساحة سطح الجسم).</p><p>&nbsp;</p><p dir="RTL">يوم تلقي العلاج الكيماوي:</p><p dir="RTL">تعطى أول جرعة من الدواء عبر الحقن في الوريد، مباشرة قبل تلقي الطفل العلاج الكيماوي. بعد العلاج الكيماوي؛ سيتناول الطفل الدواء بعد ذلك عبر الفم على الأغلب سواء أقراص أو شراب.&nbsp;</p><p dir="RTL">في الأيام التالية:</p><p dir="RTL">يمكن البدء في تناول الدواء عبر الفم بعد 12 ساعة من أخذ آخر جرعة وريدية، على أن يستمر في تناوله لمدة تصل إلى 5 أيام.&nbsp;</p><p dir="RTL">يستخدم من أجل منع أو علاج الشعور بالغثيان والقيء بعد العمليات الجراحية</p><p dir="RTL"><strong>البالغون</strong>:</p><p dir="RTL">الجرعة المعتادة الموصى بها للمرضى البالغين هي 4 ملغم، تعطى عبر الحقن في الوريد أو العضل.</p><p dir="RTL">سيتم إعطاء الدواء مباشرة قبل العملية الجراحية من أجل الوقاية من ذلك.</p><p dir="RTL">الأطفال:</p><p dir="RTL">سيقوم الطبيب بتحديد الجرعة اللازم تناولها في حالة الأطفال البالغين من العمر ما يزيد عن شهر واحد والمراهقين أيضا. الجرعة القصوى هي 4 ملغم، تعطى عبر الحقن الوريدي البطيء.&nbsp; سيتم إعطاء الدواء مباشرة قبل العملية الجراحية من أجل الوقاية من ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل متوسطة إلى شديدة في الكبد</strong></p><p dir="RTL">يجب ألا تتجاوز الجرعة اليومية 8 ملغم كحد أقصى.</p><p dir="RTL"><strong>إذا استمر شعورك بالتعب أو الغثيان</strong></p><p dir="RTL">عادة ما يبدأ تأثير دواء فوستران في خلال وقت قصير بعد الحقن. أخبر الطبيب أو الممرضة إذا استمر شعورك بالتعب أو الغثيان.</p><p dir="RTL"><strong>إذا تناولت دواء فوستران أكثر من الموصى به</strong></p><p dir="RTL">سيُعطى إليك هذا الدواء بواسطة الطبيب أو الممرضة لذلك فمن غير الوارد تلقي جرعة زائدة من الدواء، أو أن تفوتك جرعة من الدواء. أخبر الطبيب أو الممرضة إذا كنت تعتقد بأنك تناولت جرعة زائدة من الدواء أو فاتتك الجرعة.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي أو الممرضة إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL"><strong>رد الفعل التحسسي</strong></p><p dir="RTL">أخبر الطبيب أو أي فرد من الطاقم الطبي على الفور إذا كنت تعاني من رد فعل تحسسي.</p><p dir="RTL">. قد تشتمل أعراض الحساسية الآتي:</p><p dir="RTL">&bull; ألم أو ضيق أو أزيز بشكل مفاجئ في الصدر</p><p dir="RTL">&bull; تورم حول العين أو في الوجه أو الشفاه أو الفم أو اللسان.</p><p dir="RTL">طفح جلدي - بقع حمراء أو كتل دهنية مرتفعة تحت الجلد (شرى) في أي مكان من الجسم.</p><p dir="RTL">الإغماء</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض الجانبية الأقل خطورة:</strong></p><p dir="RTL"><strong>أعراض جانبية مألوفة جدا </strong><strong>(الأعراض التي قد تؤثر في أكثر من </strong><strong>1</strong><strong> من بين </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">صداع</p><p dir="RTL"><strong>أعراض جانبية مألوفة (الأعراض التي قد تؤثر في </strong><strong>1 من بين </strong><strong>10 أشخاص)</strong></p><p dir="RTL">الشعور بالدفء أو السخونة في الجسم</p><p dir="RTL">إمساك</p><p dir="RTL">تغيرات في نتائج فحوصات وظائف الكبد (وذلك إذا تناولت دواء فوستران مع دواء آخر يسمى سيسبلاتين، عدا ذلك فإن هذا العرض الجانبي غير مألوف)</p><p dir="RTL">تهيج واحمرار في موضع الحقن</p><p dir="RTL"><strong>أعراض جانبية غير مألوفة &nbsp;(الأعراض التي قد تؤثر في </strong><strong>1 من بين </strong><strong>100 شخص)</strong></p><p dir="RTL">نوبات صرعية (تشنجات أو صرع)</p><p dir="RTL">حركة غير طبيعية في الجسم أو ارتجاف</p><p dir="RTL">عدم انتظام في ضربات القلب</p><p dir="RTL">ألم في الصدر</p><p dir="RTL">انخفاض في ضغط الدم، مما يجعلك تشعر بالدوار أو الإغماء</p><p dir="RTL">الفواق</p><p dir="RTL"><strong>أعراض جانبية نادرة &nbsp;(الأعراض التي قد تؤثر في </strong><strong>1 من بين </strong><strong>1,000 شخص)</strong></p><p dir="RTL">الشعار بالدوار أو الدوخة</p><p dir="RTL">تشوش الرؤية</p><p dir="RTL">اضطراب في إيقاع ضربات القلب (قد يتسبب ذلك في بعض الأحيان في فقدان الوعي بصورة مفاجئة)</p><p dir="RTL"><strong>أعراض جانبية نادرة جدا (الأعراض التي قد تؤثر في </strong><strong>1 من بين </strong><strong>10,000 شخص)</strong></p><p dir="RTL">ضعف الرؤية أو فقدان مؤقت للبصر، وعادة ما يرجع البصر مرة أخرى في غضون 20 دقيقة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضح على العبوة أو العبوة بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">يحفظ في درجة حرارة لاتتجاوز 30 درجة مئوية . يحفظ بعيداً من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت وجود أي تلف في العبوة أو ظهور جسيمات أو بلورات بداخله.</p><p dir="RTL">لا تقم بإلقاء أية أدوية في مياه الصرف أو في النفايات المنزلية. وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في هذا الدواء هي أوندانسيترون (في صورة هيدروكلوريد ثنائي الهيدرات).</p><p dir="RTL">يحتوي كل مل من المحلول المستخدم في الحقن أو التنقيط الوريدي على 2 ملغم من مادة أوندانسيترون (في صورة أوندانسيترون هيدروكلوريد ثنائي الهيدرات).</p><p dir="RTL">تحتوي كل عبوة&nbsp; 2 مل على 4 ملغم من مادة أوندانسيترون (في صورة أوندانسيترون هيدروكلوريد ثنائي الهيدرات).&nbsp;</p><p dir="RTL">تحتوي كل عبوة&nbsp; 4 مل على 8 ملغم من مادة أوندانسيترون (في صورة أوندانسيترون هيدروكلوريد ثنائي الهيدرات).</p><p dir="RTL">باقي المكونات: حمض السيتريك أحادي الهيدرات، سيترات الصوديوم، كلوريد الصوديوم، هيدروكسيد الصوديوم، وماء من أجل الحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فوستران هو محلول رائق (شفاف) بلا لون ويُستخدم عبر الحقن أو التنقيط الوريدي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">إم إس فارما &ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Aug-19
SPM190282

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vostran 4mg/2ml Solution for Injection or Infusion
Vostran 8mg/4ml Solution for Injection or Infusion
*Vostran 2 mg/ml Solution for Injection or Infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of Vostran solution for injection or infusion contains:
2mg ondansetron (as ondansetron hydrochloride dihydrate)
Each Vial with 2ml contains 4mg Vostran (as ondansetron hydrochloride dihydrate).
Each Vial with 4ml contains 8mg Vostran (as ondansetron hydrochloride dihydrate).
For the full list of excipients, see section 6.1


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection or Infusion
Clear colourless solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults:</u></p><p>Management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy, Prevention and treatment of post-operative nausea and vomiting (PONV).</p><p><u>Paediatric Population:</u></p><p>Management of chemotherapy-induced nausea and vomiting in children aged &ge;6 months.</p><p>Prevention and treatment of post-operative nausea and vomiting in children aged &ge; 1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>Chemotherapy and radiotherapy induced nausea and vomiting:</u></p><p><em>Adults:&nbsp;</em>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of ondansetron should be flexible in the range of 8-32 mg a day and selected as shown below.</p><p><em>Emetogenic chemotherapy and radiotherapy:</em></p><p>Ondansetron can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration.</p><p>For most patients receiving emetogenic chemotherapy or radiotherapy, ondansetron 8 mg should be administered as a slow intravenous injection (in not less than 30 seconds) or intramuscular injection, immediately before treatment followed by 8 mg orally twelve hourly.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ondansetron should be continued for up to 5 days after a course of treatment.</p><p><em>Highly emetogenic chemotherapy</em>: For patients receiving highly emetogenic chemotherapy, e.g. high-dose cisplatin, ondansetron can be given either by oral, rectal, intravenous or intramuscular administration. Ondansetron has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy:</p><p>&bull; A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy.</p><p>&bull; A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular doses of 8 mg two to four hours apart, or by a constant infusion of 1 mg/hour for up to 24 hours.</p><p>&bull; A maximum initial intravenous dose of 16 mg diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over not less than 15 minutes immediately before chemotherapy. The initial dose of ondansetron may be followed by two additional 8 mg intravenous doses (in not less than 30 seconds) or intramuscular doses four hours apart.</p><p>&bull; A single dose greater than 16 mg must not be given due to dose dependent increase of QT-prolongation risk (see sections 4.4, 4.8 and 5.1)</p><p>The selection of dose regimen should be determined by the severity of the emetogenic challenge.</p><p>The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ondansetron should be continued for up to 5 days after a course of treatment.</p><p><u>Paediatric Population:</u></p><p><u>CINV in children aged &ge;6 months and adolescents:</u></p><p>The dose of CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes.</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing &ndash; see sections 4.4 and 5.1</p><p>Ondansetron hydrochloride should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid (see section 6.6) and infused intravenously over not less than 15 minutes.</p><p>There are no data from controlled clinical trials on the use of Ondansetron Injection in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of Ondansetron Injection for radiotherapy-induced nausea and vomiting in children.</p><p>Dosing by BSA:</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m<sup>2</sup>. The single intravenous dose must not exceed 8 mg.</p><p>Oral dosing can commence twelve hours later and may be continued for up to 5 days. (Table 1).</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><u>Table 1: BSA-based dosing for Chemotherapy - Children aged &ge;6 months and adolescents</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1<sup>a,b</sup></p></td><td style="vertical-align:top"><p>Days 2-6<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus 2 mg syrup after 12 hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&ge;0.6 m<sup>2</sup>&nbsp;to &le; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus 4 mg syrup after 12 hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2&nbsp;</sup>IV plus 8 mg syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>8 mg syrup or tablet every 12 hours</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;The intravenous dose must not exceed 8 mg.</p><p><sup>b&nbsp;</sup>The total daily dose over 24 hours ( given as divided doses) must not exceed adult dose of 32 mg.</p><p><strong>Please note: Not all pharmaceutical forms may be available.</strong></p><p><u>Dosing by bodyweight:</u></p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see sections 4.4 and 5.1).</p><p>Ondansetron should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/Kg. The single intravenous dose must not exceed 8 mg.</p><p>Two further intravenous doses may be given in 4-hourly intervals.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days. (Table 2).</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><u>Table 2: Weight-based dosing for Chemotherapy - Children aged &ge;6 months and adolescents</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Day1<sup>(a,b)</sup></p></td><td style="vertical-align:top"><p>Days 2-6<sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&le;10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4-hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4-hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every 12 hrs</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;The intravenous dose must not exceed 8 mg.</p><p><sup>b</sup>&nbsp;The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><strong>Please note: Not all pharmaceutical forms may be available.</strong></p><p><em>Elderly:</em></p><p>In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes.</p><p>In patients 75 years of age or older, the initial intravenous dose of Ondansetron should not exceed 8 mg. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes.</p><p>The initial dose of 8 mg may be followed by two further intravenous doses of 8 mg, infused over 15 minutes and given no less than four hours apart. (see section 5.2)</p><p><em><u>Patients with renal impairment:</u></em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration is required.</p><p><em><u>Patients with Hepatic impairment:</u></em></p><p>Clearance of ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded and therefore parenteral or oral administration is recommended.</p><p><em><u>Patients with poor sparteine/debrisoquine metabolism</u></em><u>:</u></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p><p><u>Post-operative nausea and vomiting (PONV):</u></p><p><em><u>Adults:</u></em></p><p>For the prevention of PONV: Ondansetron can be administered orally or by intravenous or intramuscular injection.</p><p>Ondansetron may be administered as a single dose of 4 mg given by intramuscular or slow intravenous injection at induction of anaesthesia.</p><p>For treatment of established PONV: A single dose of 4 mg given by intramuscular or slow intravenous injection is recommended.</p><p><u>Paediatric population:</u></p><p><u>PONV in children aged &ge; 1 month and adolescents.</u></p><p>For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose 0.1 mg/Kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>For the treatment of PONV after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of Ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1mg/kg up to a maximum of 4mg.</p><p>There are no data on the use of Ondansetron in the treatment of PONV children below 2 years of age.</p><p><em><u>Elderly:</u></em></p><p>There is limited experience in the use of ondansetron in the prevention and treatment of PONV in the elderly however ondansetron is well tolerated in patients over 65 years receiving chemotherapy.</p><p><em><u>Patients with renal impairment:</u></em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration is required.</p><p><em><u>Patients with hepatic impairment:</u></em></p><p>Clearance of ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded and therefore parenteral or oral administration is recommended.</p><p><em><u>Patients with poor sparteine/debrisoquine metabolism:</u></em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing are required.</p><p>Method of administration</p><p>For intravenous injection or intramuscular injection or intravenous infusion after dilution.</p><p>For instructions on dilution of the product before administration, see section 6.6</p><p>Prescribers intending to use ondansetron in the prevention of delayed nausea and vomiting associated with chemotherapy or radiotherapy in adults, adolescents or children should take into consideration current practice and appropriate guidelines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concomitant use with apomorphine (see section 4.5) Hypersensitivity to any component of the preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT<sub>3</sub>receptor antagonists.</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitive reactions.</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs)). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p>Ondansetron injection contains 2.5 mmol (or 57.9 mg) sodium per maximum daily dose of 32 mg. To be taken into consideration by patients on a controlled sodium diet.</p><p><u>Paediatric Population:</u></p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeuticagents should be monitored closely for impaired hepatic function.</p><p><u>CINV:</u></p><p>When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m<sup>2</sup>&nbsp;followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross trial comparison indicates similar efficacy for both regimens (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no pharmacokinetic interactions when ondansetron is administered with alcohol, temazepan, Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities. (See section 4.4).</p><p>Use of Ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of Ondansetron with cardiotoxic drugs (e.g. anthracyclines (such as doxorubicin, daunorubicin or trastuzumab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias (See section 4.4).</p><p>Serotonergic Drugs (e.g. SSRIs and SNRIs):</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs). (See section 4.4)</p><p><em>Apomorphine:</em>&nbsp;Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p><em>Phenytoin, Carbamazepine and Rifampicin:</em>&nbsp;In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p><em>Tramadol:</em></p><p>Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The safety of ondansetron for use in human pregnancy has not been established. Evaluation of experimental animal studies does not indicate direct or indirect harmful effects with respect to the development of the embryo, or foetus, the course of gestation and pre- and post-natal development. However as animal studies are not always predictive of human response the use of ondansetron in pregnancy is not recommended.</p><p><u>Breast-feeding</u></p><p>Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving ondansetron should not breast-feed their babies.</p><p><u>Fertility</u></p><p>There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities are predicted from the pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (&ge;1/10), common (<!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_7" o:spid="_x0000_i1027" type="#_x0000_t75"
 alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png"
 style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="spc~25808~6~image1"/>
</v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />1/100 and &lt;1/10), uncommon (<!--[if gte vml 1]><v:shape
 id="Picture_x0020_6" o:spid="_x0000_i1026" type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png"
 style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="spc~25808~6~image1"/>
</v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />1/1000 to &lt;1/100), rare (<!--[if gte vml 1]><v:shape
 id="Picture_x0020_5" o:spid="_x0000_i1025" type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png"
 style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="spc~25808~6~image1"/>
</v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image1.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />1/10,000 and &lt;1/1000) and very rare (&lt;1/10,000). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare and very rare events were generally determined from post-marketing spontaneous data.</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron. The adverse event profiles in children And adolescents were comparable to that seen in adults.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia)<sup>(1)</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dizziness during rapid i.v. administration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Transient visual disturbances (eg. blurred vision) predominantly during IV administration.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Transient blindness predominantly during intravenous administration<sup>(2)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>QTc prolongation (including Torsade de Pointes).</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Sensation of warmth or flushing.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypotension.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hiccups.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Constipation.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Asymptomatic increases in liver function tests&nbsp;<sup>(3)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>local IV injection site reactions.</p></td></tr></tbody></table><p>1. Observed without definitive evidence of persistent clinical sequelae.</p><p>2. The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.</p><p>3. These events were observed commonly in patients receiving chemotherapy with cisplatin.</p><p><strong>&nbsp;</strong></p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:1pt;margin-top:6pt;width:375.05pt;height:94.5pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=right dir=RTL style='text-align:left;mso-layout-grid-align:
    none;text-autospace:none'><span dir=LTR style='font-size:8.0pt;line-height:
    107%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>National
    Pharmacovigilance and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:8.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:
    TimesNewRomanPSMT'>Fax: +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:8.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:
    TimesNewRomanPSMT'>Call NPC at +966-11-2038222</span><span
    style='font-size:8.0pt;line-height:115%'> ,</span><span style='font-size:
    8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:
    TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;line-height:115%;mso-layout-grid-align:none;text-autospace:none'><span
    style='font-size:8.0pt;line-height:115%'>E</span><span style='font-size:
    8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:
    TimesNewRomanPSMT'>xt 2317-2356-2340<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:8.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:
    TimesNewRomanPSMT'>SFDA Call Center: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    class=MsoHyperlink><span style='font-size:8.0pt;line-height:115%;
    font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;text-decoration:none;text-underline:none'><span style='mso-list:
    Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=LTR></span><span
    style='font-size:8.0pt;line-height:115%;font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:8.0pt;line-height:
    115%;font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    class=MsoHyperlink><span style='font-size:8.0pt;line-height:115%;
    font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-bottom:10.0pt;mso-add-space:
    auto;text-indent:-18.0pt;line-height:115%;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-size:8.0pt;line-height:115%;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    8.0pt;line-height:115%;font-family:"Times New Roman",serif'>Website:
    www.sfda.gov.sa</span><span style='font-size:8.0pt;line-height:115%;
    font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="132" alt="Text Box: National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222 ,
Ext 2317-2356-2340
•	SFDA Call Center: 19999
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa
" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and Signs</p><p>There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second degree AV block.</p><p>Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p>Cases consistent with serotonin syndrome have been reported in young children following oral overdose.</p><p><u>Paediatric population</u></p><p>Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p><u>Treatment</u></p><p>There is no specific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code:- A04 Antiemetics and antinauseants</p><p>ATC group:- A04AAO1 Serotonin (5HT<sub>3</sub>) antagonist</p><p><u>Mechanism of Action</u></p><p>Ondansetron is a potent, highly selective 5HT<sub>3&nbsp;</sub>receptor-antagonist.</p><p>Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT<sub>3&nbsp;</sub>receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT<sub>3&nbsp;</sub>receptors on neurons located both in the peripheral and central nervous system.</p><p>The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p>The role of ondansetron in opiate-induced emesis is not yet established.</p><p><u>QT Prolongation</u></p><p>The effect of ondansetron on the QTc interval was evaluated in a double blind, randomised, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women.. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec. No significant changes were seen in the measured electrocardiographic PR or QRS intervals.</p><p><u>Paediatric Population:</u></p><p><em><u>CINV</u></em></p><p>The efficacy of Ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m<sup>2</sup>&nbsp;intravenous and ondansetron 4 mg orally after 8 to 12 hours or ondansetron 0.45 mg/Kg intravenous and placebo after 8 to 12 hours. Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49 % (5mg/m<sup>2</sup>&nbsp;intravenous and ondansetron 4 mg orally) and 41 % (0.45 mg/Kg intravenous and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>A double-blind randomised placebo-controlled trial(S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><p>73% of patients when ondansetron was administered intravenously at a dose of 5mg/m<sup>2</sup>&nbsp;intravenous together with 2-4 mg dexamethasone orally.</p><p>71% of the patients when ondansetron was administered as a syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.</p><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children receive three 0.15 mg/Kg doses of intravenous ondansetron, administered at 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>Another open-label, non-operative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/Kg ondansetron followed by two ondansetron doses of 4mg for children aged &lt; 12 years and 8 mg for children aged &ge; 12 years (total no. of children n = 28). Complete control of emesis was achieved in 42% of patients.</p><p><u>PONV</u></p><p>The efficacy of a single dose of Ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age &ge; 44 weeks, weight &ge; 3 Kg). Included subjects were scheduled to undergo effective surgery under general anaesthesia and had an ASA status &le; III. A single dose of ondansetron 0.1 mg/Kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron (28% vs. 11%, p&lt;0.0001).</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735)) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p><u>Table 3 Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24 hours</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_4" o:spid="_x0000_i1027" type="#_x0000_t75"
   alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png"
   style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="spc~25808~6~image2"/>
  </v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_3" o:spid="_x0000_i1026"
   type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png"
   style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="spc~25808~6~image2"/>
  </v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1025"
   type="#_x0000_t75" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png"
   style='width:9.75pt;height:9.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
    o:title="spc~25808~6~image2"/>
  </v:shape><![endif]--><img width="13" height="13" alt="https://www.medicines.org.uk/emc/images/spc/spc~25808~6~image2.png" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30ng/ml are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids.</p><p>Following administration of ondansetron suppository, plasma ondansetron concentrations become detectable between 15 and 60 minutes after dosing. Concentrations rise in an especially linear fashion, until peak concentrations of 20-30 ng/ml are attained, typically 6 hours after dosing. Plasma concentrations then fall, but at a slower rate than observed following oral dosing due to continued absorption of ondansetron.</p><p>Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age-related increases in both oral bioavailability (65%) and half-life (five hours) of ondansetron.</p><p>A 4mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65 ng/ml. Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/ml are attained within 10 minutes of injection.</p><p>Distribution</p><p>The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140 L. Equivalent systemic exposure is achieved after intramuscular and intravenous administration of ondansetron.</p><p>Ondansetron is not highly protein bound (70-76%).</p><p>The absolute bioavailability of ondansetron from the suppository is approximately 60% and is not affected by gender.</p><p>Biotransformation</p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics.</p><p>Elimination</p><p>Less than 5% of the absorbed dose is excreted unchanged in the urine. Terminal half-life is about 3 hours.</p><p><u>The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</u></p><p><u>The half life of the elimination phase following suppository administration is determined by the rate of ondansetron absorption, not systemic clearance and is approximately 6 hours. Females show a small, clinically insignificant, increase in half-life in comparison with males.</u></p><p><u>Special Patient Populations</u></p><p><u>Gender</u></p><p><u>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</u></p><p><u>Children and Adolescents (aged 1 month to 17 years)</u></p><p>In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4 month was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were similar between the different age group populations. Use of weight-based dosing compensates for age-related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to 4 months. Volume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is not likely to be clinically relevant.</p><p><em>Elderly</em></p><p>Early phase I studies in healthy elderly volunteers have showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly.</p><p>Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge; 75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for IV dosing (see section 4.2).</p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60 ml/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4h). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&#39;s pharmacokinetics to be essentially unchanged following intravenous administration.</p><p><em>Hepatic impairment</em></p><p>Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15-32 hours) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism. The pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity and carcinogenic potential.</p><p>Ondansetron and its metabolites accumulate in the milk of rats at a milk<strong>:</strong>plasma ratio of 5.2<strong>:</strong>1.</p><p>A study in cloned human cardiac ion channels has shown ondansetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid monohydrate</p><p>Sodium citrate</p><p>Sodium chloride</p><p>Sodium hydroxide (for pH adjustment)</p><p>Water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened
2 years
Injection
After first opening the medicinal product should be used immediately.
Infusion
Chemical and physical in-use stability has been demonstrated for 7 days at 25°C and 2-8°C with the solutions given in section 6.6.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C, protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear Tubular Glass Vials (3 ml), Rubber stopper 13 mm.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution must not be sterilized in an autoclave.</p><p>Ondansetron Injection should only be admixed with those infusion solutions which are recommended:</p><p>Sodium Chloride Intravenous Infusion BP 0.9%w/v</p><p>Glucose Intravenous Infusion BP 5%w/v</p><p>Mannitol Intravenous Infusion BP 10%w/v</p><p>Ringers Intravenous Infusion</p><p>Potassium Chloride 0.3%w/v and Sodium Chloride 0.9%w/v Intravenous Infusion BP</p><p>Potassium Chloride 0.3%w/v and Glucose 5%w/v Intravenous Infusion BP</p><p>The stability of Ondansetron Injection after dilution with the recommended infusion fluids have been demonstrated in concentrations 0.016 mg/ml and 0.64 mg/ml.</p><p>Compatibility studies have been undertaken in polyvinyl chloride infusion bags with polyvinyl chloride administration sets, polyethylene infusion bags, Type 1 glass bottles and polypropylene syringes. Dilutions of Ondansetron Injection in 10% mannitol injection, ringer&#39;s injection, 0.3% potassium chloride and 0.9% sodium chloride injection, 0.3% potassium chloride and 5% dextrose injection, 0.9% sodium chloride injection and 5% glucose injection have been demonstrated to be stable in polyvinyl chloride infusion bags and polyvinyl chloride administration sets, polyethylene infusion bags, Type 1 glass bottles and polypropylene syringes.</p><p><em>Compatibility with other drugs:</em>&nbsp;Ondansetron Injection may be administered by intravenous infusion using 0.9% sodium chloride and 5% dextrose injection at 1mg/hour, e.g. from an infusion bag or syringe pump. The following drugs may be administered via the Y-site of the Ondansetron Injection giving set for ondansetron concentrations of 16 to 160 micrograms/ml (e.g. 8 mg/500 ml and 8 mg/50 ml respectively);</p><p><em>Cisplatin:</em>&nbsp;Concentrations up to 0.48 mg/ml (e.g. 240 mg in 500 ml) administered over one to eight hours.</p><p><em>Carboplatin:</em>&nbsp;Concentrations in the range 0.18 mg/ml to 9.9 mg/ml (e.g. 90 mg in 500 ml to 990 mg in 100 ml), administered over ten minutes to one hour.</p><p><em>Etoposide:</em>&nbsp;Concentrations in the range 0.14 mg/ml to 0.25 mg/ml (e.g. 72 mg in 500 ml to 250 mg in 1 litre), administered over thirty minutes to one hour.</p><p><em>Ceftazidime:</em>&nbsp;Doses in the range 250 mg to 2000 mg reconstituted with Water for Injections BP as recommended by the manufacturer (e.g. 2.5 ml for 250 mg and 10 ml for 2g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.</p><p><em>Cyclophosphamide:</em>&nbsp;Doses in the range 100 mg to 1g, reconstituted with Water for Injections BP, 5 ml per 100 mg cyclophosphamide, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.</p><p><em>Doxorubicin:</em>&nbsp;Doses in the range 10-100mg reconstituted with Water for Injections BP, 5 ml per 10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately 5 minutes.</p><p><em>Dexamethasone:</em>&nbsp;Dexamethasone sodium phosphate 20mg may be administered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 or 16mg of ondansetron diluted in 50-100 ml of a compatible infusion fluid over approximately 15 minutes. Compatibility between dexamethasone sodium phosphate and ondansetron has been demonstrated supporting administration of these drugs through the same giving set resulting in concentrations in line of 32 microgram - 2.5 mg/ml for dexamethasone sodium phosphate and 8 microgram &ndash; 0.75 mg/ml for ondansetron.</p><p>The solution is to be visually inspected prior to use (also after dilution). Only clear solutions practically free from particles should be used.</p><p>The diluted solutions should be stored protected from light.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug-19
SPC-030-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>